Latest Breaking News On - Accustem sciences - Page 1 : comparemela.com

AccuStem Sciences, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024

AccuStem Sciences, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 0.526602 million compared to USD 0.833341.

Accustem sciences incAccustem sciences

AccuStem Sciences, Inc Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer

AccuStem Sciences, Inc Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomUnited statesWendy blosserAccustem stemprintTiziana life sciencesAccustem sciencesAccustem sciences incStem sciencesRoyal marsden hospitalExact sciencesChief executive officerInstituto europeoDie experten

Goldman Small Cap Research Publishes New Research Report on AccuStem Sciences, Inc

Goldman Small Cap Research Publishes New Research Report on AccuStem Sciences, Inc
pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.

Rob goldmanExchange commissionOpportunity researchTradigital marketing group incA goldman small cap researchNeither goldman small cap researchAccustem sciences incGoldman small cap researchGoldman sachs coPiper jaffrayAccustem sciencesChanging technologyUniquely gearedEarly stagePotential acquisition lieSmall cap research

AccuStem Sciences, Inc : AccuStem Sciences Announces Extension of its US Patent Application for SPARE Test for Patients with Breast Cancer

LONDON and PHOENIX, May 02, 2023 (GLOBE NEWSWIRE) AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced today

United statesCity ofUnited kingdomWendy blosserJeff fenstererRisk factor in accustem sciences incTrademark officeExchange commissionAccustem sciences incStem sciencesChief executive officerRisk factorAccustem sciencesAnnual reportChief operationsChief executive

AccuStem Sciences, Inc : AccuStem Announces Adjournment of Annual Meeting of Stockholders

LONDON and PHOENIX, Oct. 10, 2022 (GLOBE NEWSWIRE) AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced today

United statesCity ofUnited kingdomWendy blosserJeff fenstererExchange commissionAccustem sciences incExchange commission onRisk factor in accustem sciences incStem sciencesAnnual meetingRisk factorAccustem sciencesAnnual reportChief operationsChief executive